ANI Pharmaceuticals (ANIP) Upgraded to “Hold” at BidaskClub

BidaskClub upgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a sell rating to a hold rating in a report published on Friday morning.

A number of other equities analysts have also recently weighed in on the stock. ValuEngine cut shares of ANI Pharmaceuticals from a hold rating to a sell rating in a research report on Monday, October 8th. Cantor Fitzgerald set a $74.00 price target on shares of ANI Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, October 3rd. Canaccord Genuity set a $75.00 price target on shares of ANI Pharmaceuticals and gave the stock a buy rating in a research report on Thursday, August 16th. Finally, Zacks Investment Research cut shares of ANI Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, July 10th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The company presently has an average rating of Hold and an average target price of $72.67.

Shares of NASDAQ ANIP traded up $0.40 during midday trading on Friday, reaching $54.38. 45,492 shares of the stock were exchanged, compared to its average volume of 102,748. The stock has a market cap of $668.70 million, a price-to-earnings ratio of 15.06 and a beta of 2.62. ANI Pharmaceuticals has a 12 month low of $49.76 and a 12 month high of $74.70. The company has a quick ratio of 2.89, a current ratio of 3.84 and a debt-to-equity ratio of 1.08.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $1.13 earnings per share for the quarter, missing analysts’ consensus estimates of $1.34 by ($0.21). The firm had revenue of $47.27 million for the quarter, compared to the consensus estimate of $50.70 million. ANI Pharmaceuticals had a return on equity of 27.76% and a net margin of 0.06%. On average, research analysts anticipate that ANI Pharmaceuticals will post 4.49 EPS for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Aperio Group LLC lifted its position in ANI Pharmaceuticals by 21.3% in the 2nd quarter. Aperio Group LLC now owns 5,799 shares of the specialty pharmaceutical company’s stock valued at $387,000 after acquiring an additional 1,019 shares in the last quarter. Strs Ohio lifted its position in ANI Pharmaceuticals by 17.3% in the 2nd quarter. Strs Ohio now owns 12,200 shares of the specialty pharmaceutical company’s stock valued at $814,000 after acquiring an additional 1,800 shares in the last quarter. Cadence Capital Management LLC lifted its position in ANI Pharmaceuticals by 83.3% in the 2nd quarter. Cadence Capital Management LLC now owns 46,108 shares of the specialty pharmaceutical company’s stock valued at $3,080,000 after acquiring an additional 20,947 shares in the last quarter. Boston Partners bought a new stake in ANI Pharmaceuticals in the 2nd quarter valued at $3,144,000. Finally, Phocas Financial Corp. bought a new stake in ANI Pharmaceuticals in the 2nd quarter valued at $2,788,000. 60.67% of the stock is currently owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis.

See Also: 52-Week High/Low

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply